Bioengineering stents are also called antibody-coated stents.
This type of stent is different from drug-coated stents (DCS) because it does not contain a polymer or drug.
Antibodies from the stent’s surface attract endothelial progenitor cells (EPC) that come from human bone marrow.
As a result, it helps speed up the lining of the arteries with cells (endothelialization), promoting natural healing.
It provides rapid coverage of the stent surface with a reduced risk of early and late thrombosis (blood clots).
A bioengineering stent is a stainless steel coronary artery stent coated with a biocompatible matrix with applied CD34-specific antibodies, surface antigens present on circulating endothelial progenitor cells (EPC).
The described process results in a fast and controlled endothelial treatment, thereby simplifying and speeding up the natural treatment process while minimizing the time during which the stent surface poses the risk of thrombosis.
As a result of this rapid endothelialization, the manufacturer recommends a duration of double antiplatelet therapy of only 4 weeks.
This has a potential advantage over traditional stenting of patients with pure metal stents requiring non-cardiac surgery, taking into account the required period of antiplatelet therapy.
These stents can be very useful for patients requiring urgent non-cardiac surgery.